CGH
NBIX icon

Crossmark Global Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Crossmark Global Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Buy
8,701
+234
+3% +$34.7K 0.02% 539
2026
Q1 		$1.12M Buy
8,467
+100
+1% +$13.3K 0.02% 582
2025
Q4 		$1.19M Buy
8,367
+509
+6% +$73.7K 0.02% 557
2025
Q3 		$1.1M Sell
7,858
-164
-2% -$22.2K 0.02% 596
2025
Q2 		$1.01M Sell
8,022
-763
-9% -$87.5K 0.02% 605
2025
Q1 		$972K Buy
8,785
+320
+4% +$40.5K 0.02% 615
2024
Q4 		$1.16M Sell
8,465
-22
-0.3% -$2.72K 0.02% 542
2024
Q3 		$978K Buy
8,487
+1,204
+17% +$165K 0.02% 620
2024
Q2 		$1M Sell
7,283
-657
-8% -$90.1K 0.02% 587
2024
Q1 		$1.09M Sell
7,940
-116
-1% -$15.8K 0.02% 588
2023
Q4 		$1.06M Sell
8,056
-491
-6% -$56.5K 0.02% 577
2023
Q3 		$977K Sell
8,547
-489
-5% -$51.5K 0.02% 577
2023
Q2 		$929K Sell
9,036
-379
-4% -$37K 0.02% 612
2023
Q1 		$953K Buy
9,415
+212
+2% +$22.1K 0.02% 596
2022
Q4 		$1.1M Sell
9,203
-83
-0.9% -$9.72K 0.03% 544
2022
Q3 		$986K Sell
9,286
-105
-1% -$10.7K 0.03% 549
2022
Q2 		$916K Sell
9,391
-100
-1% -$9.23K 0.02% 596
2022
Q1 		$890K Sell
9,491
-10
-0.1% -$847 0.02% 670
2021
Q4 		$809K Sell
9,501
-980
-9% -$90.1K 0.02% 702
2021
Q3 		$1M Sell
10,481
-90
-0.9% -$8.5K 0.02% 612
2021
Q2 		$1.03M Buy
+10,571
New +$1.01M 0.02% 604
2018
Q4 		– Sell
-2,496
Closed -$307K – 1497
2018
Q3 		$307K Sell
2,496
-220
-8% -$25K 0.01% 1302
2018
Q2 		$267K Sell
2,716
-370
-12% -$33.1K 0.01% 1387
2018
Q1 		$256K Sell
3,086
-1,066
-26% -$90K 0.01% 1370
2017
Q4 		$322K Sell
4,152
-514
-11% -$35.1K 0.01% 1330
2017
Q3 		$286K Buy
+4,666
New +$246K 0.01% 1349
2016
Q3 		$286K Buy
+4,666
New +$232K 0.01% 1349

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Crossmark Global Holdings's NBIX Position: Q2 2026 in Review

Crossmark Global Holdings increased its Neurocrine Biosciences (NBIX) stake by 2.8% in Q2 2026, buying an estimated $34.7K and bringing the position to 8,701 shares worth $1.47M. The position accounts for 0.02% of the portfolio, ranked #539.

Crossmark Global Holdings first reported a position in NBIX in Q3 2016 and has held it in 27 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Crossmark Global Holdings held 8,701 shares of Neurocrine Biosciences worth $1.47M as of Q2 2026.
  • Crossmark Global Holdings bought 234 Neurocrine Biosciences shares in Q2 2026, an estimated $34.7K.
  • Neurocrine Biosciences made up 0.02% of Crossmark Global Holdings's portfolio in Q2 2026, its #539 holding.
  • Crossmark Global Holdings first reported a position in Neurocrine Biosciences in Q3 2016 and has held it in 27 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.